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Abstract
Introduction—Recent studies suggested that muscle mass and muscle strength may 
independently or synergistically affect aging-related health outcomes in older adults; however, 
prospective data on mortality in the general population are sparse.
Methods—We aimed to prospectively examine individual and joint associations of low muscle 
mass and low muscle strength with all-cause mortality in a nationally representative sample. This 
study included 4,449 participants aged 50 years and older from the National Health and Nutrition 
Examination Survey (NHANES) 1999–2002 with public-use 2011 linked mortality files. Weighted 
multivariable logistic regression models were adjusted for age, sex, race, BMI, smoking, alcohol 
use, education, leisure-time physical activity (LTPA), sedentary time, and comorbid diseases.
Results—Overall, the prevalence of low muscle mass was 23.1% defined by appendicular lean 
mass (ALM) and 17.0% defined by ALM/BMI, and the prevalence of low muscle strength was 
19.4%. In the joint analyses, all-cause mortality was significantly higher among individuals with 
low muscle strength, whether they had low muscle mass (OR 2.03, 95% CI, 1.27–3.24 for ALM; 
OR 2.53, 95% CI, 1.64–3.88 for ALM/BMI) or not (OR 2.66, 95% CI 1.53–4.62 for ALM; OR 
2.17, 95% CI 1.29–3.64 for ALM/BMI). In addition, the significant associations between low 
muscle strength and all-cause mortality persisted across different levels of metabolic syndrome 
(MetS), sedentary time, and LTPA.
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Conclusions—Low muscle strength was independently associated with elevated risk of all-
cause mortality, regardless of muscle mass, MetS, sedentary time, or LTPA among US older 
adults, indicating the importance of muscle strength in predicting aging-related health outcomes in 
older adults. Key words: Muscle Mass; Muscle Strength; Mortality; Sarcopenia; Aging
Introduction
Since 1989, when Rosenberg originally proposed the term sarcopenia, defined as an age-
related decline in muscle mass among the elderly (1), sarcopenia has been increasingly 
recognized as a common, complex, and costly state of impaired health status in older 
individuals. It is well accepted that if sarcopenia progresses beyond the lower threshold of 
muscle functional capacity, it will eventually lead to disability, frailty, and mortality (2–5). 
As two integral components of muscular function, muscle mass and muscle strength are 
intimately linked. However, there is no universal consensus on optimal assessment methods 
and diagnostic criteria for sarcopenia in older adults. In particular, it remains controversial 
how muscle mass should be considered in combination with muscle strength/weakness 
and/or physical performance in the assessment of sarcopenia.
Recent evidence from longitudinal studies indicates that age-related decline in muscle 
strength was not proportionally related to muscle mass loss (6). Further, some studies have 
shown that low muscle strength was strongly associated with poor health status and 
mortality than low muscle mass (7–10), especially among elderly persons with chronic 
medical conditions (11, 12). The Foundation for the National Institutes of Health Sarcopenia 
Project (FNIH) proposed cutoff values for clinically relevant low muscle mass and grip 
strength based on their associations with incident mobility impairment (13), but there is a 
lack of prospective data on other health-related outcomes, including mortality. Also, though 
recommended by the FNIH, grip strength has not widely been accepted as a surrogate of 
overall muscle strength (14). Some studies suggested that participants with low knee 
extensor strength performed worse in physical performance tests than in tests of grip 
strength (15, 16). It is unclear whether or to what extent low muscle mass and lower-
extremity muscle strength were independently or jointly associated with health outcomes in 
older and elderly adults.
In addition, LTPA and sedentary time are important lifestyle behaviors that are highly 
correlated with adiposity and muscle mass and/or function (17–19). Metabolic syndrome, a 
constellation of metabolic abnormalities including visceral obesity, glucose intolerance, 
hypertension, and dyslipidemia, may explain the relationship between muscle mass/strength 
and obesity-associated outcomes (20). However, few studies have specifically examined the 
effects of the interrelationship with muscle mass and muscle strength on health outcomes.
In a nationally representative sample of US adults aged 50 years and older from the 
NHANES, we aimed to 1) compare basic characteristics between participants with and 
without low muscle mass, and between those with and without low muscle strength; 2) 
calculate the prevalence of low muscle mass and low muscle strength and their combination 
subgroups stratified by sex and race, respectively; 3) prospectively examine individual or 
joint associations between low muscle mass/strength and all-cause mortality; and 4) 
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additionally examine the effects of the joint associations between low muscle mass/strength 
and MetS, sedentary time, LTPA on all-cause mortality.
Method and materials
Study population
The data were from the National Health and Nutrition Examination Survey (NHANES), a 
nationally representative, complex, and multistage probability survey of the US civilian non-
institutionalized population. All data, study design, and procedures, including 
questionnaires, results of examinations, and findings of laboratory components, are 
publically available online(21). The National Centers for Health Statistics Ethics Review 
Board approved the study protocol, and each participant provided written informed consent. 
Participants in NHANES were interviewed in their homes and underwent a standardized 
physical examination in a mobile examination center. Self-reported information on 
demographics, socioeconomic status, health conditions, and health behaviors were obtained 
during the interview. The examination component consisted of medical, dental, and 
physiological measurements, as well as laboratory tests administered by highly trained 
medical personnel.
The two cycle surveys (NHANES 1999–2000 and 2001–2002) were combined for this 
analysis. A total of 4,449 participants were included and satisfied using the following 
criteria: 50 years of age and older who underwent physical examination, were not pregnant, 
and had measurements of body composition and muscle strength, and laboratory results.
Mortality data
Public-use Linked Mortality Files are available for continuous NHANES 1999–2002. These 
files provide mortality data from the date of survey enrollment through December 31, 2011. 
Mortality source and cause of death were determined using death certificates. Cause of death 
followed the 9th revision International Statistical Classification of Disease, Injuries, and 
Cause of Death guidelines.
Demographic and comorbidities
Age, race (non-Hispanic white, non-Hispanic black, Hispanic and others), sex, and 
education were obtained from self reports. Smoking was categorized as never smokers and 
smokers. Never smokers were those who reported smoking fewer than 100 cigarettes during 
their lifetime (22). Alcohol users were those who had at least 12 drinks in the last 12 months 
(23). We used information on leisure-time physical activity (LTPA) over the past 30 days, 
which was obtained during the interview at home. LTPA was categorized into no LTPA, less 
than the recommended goal (>0 and <750 MET/week), and exceeding the recommended 
goal (≥ 750 MET/week)(24). Sedentary time (time watching TV or video or using a 
computer) per average day over the last 30 days was asked in the household interview. The 
cut-points were >2 hours per day for TV, >1 hour per day for computer use, and >3 hours for 
screen time (25).
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Hypertension was defined as blood pressure ≥ 130/85 mmHg or treatment for hypertension; 
in this study, cardiovascular diseases (CVD) included congestive heart failure, coronary 
heart disease (angina pectoris, heart attack), stroke, and hypertension. Self-report history 
was obtained for medical comorbidities by asking the question, “Has a doctor or other health 
professional ever told you that you had (disease state): congestive heart failure, coronary 
heart disease (angina pectoris, heart attack), stroke, cancer or malignancy, diabetes mellitus.” 
A participant was defined as having self-reported chronic obstructive pulmonary disease 
(COPD) if the participant reported having been told that he or she had chronic bronchitis and 
still had it or if he or she reported that he or she had emphysema. A chronic kidney disease 
(CKD) was deﬁned as an eGFR of <60 mL/minute/1.73 m2, according to the deﬁnition 
proposed by the National Kidney Foundation - Kidney Disease Outcomes Quality Initiative 
work group and the Kidney Disease: Improving Global Outcomes(26, 27).
Muscle mass
Body composition measures were assessed by certified radiology technologists using a 
DEXA QDR-4500 Hologic scanner (Hologic, Inc., Bedford, MA). Subjects taller than 192.5 
cm or weighing >136.4kg were excluded from the assessment. The densitometer uses an X-
ray source to scan participants in supine position on the tabletop with their feet in a neutral 
position and hands flat by their side. Two NHANES cycles performed similar operation 
procedures. Low muscle mass was defined using the Foundation for the National Institutes 
of Health Sarcopenia Project (FNIH) proposed definitions: appendicular lean mass (ALM) 
and ALM divided by BMI. The cutoffs were <19.75 kg and <0.789 for men, and <15.02 kg 
and <0.512 for women (13).
Muscle strength
Muscle strength is the ability to exert a maximal amount of force against a resistance (28). 
Isokinetic strength testing was completed on survey participants aged 50 years and older. A 
Kin Com MP dynamometer (Chattanooga Group, Inc, Chattanooga, TN) was used to 
evaluate knee extensor strength, which in turn was used to quantify muscle strength.
Metabolic syndrome
The five individual metabolic syndrome (MetS) components were assessed from the 
examination data or laboratory data in NHANES 1999–2002. The MetS was defined 
according to the National Cholesterol Education Program’s Adult Treatment Panel III report 
(NCEP/ATPIII) (29). An individual was diagnosed as having MetS if at least three of the 
following five criteria are satisfied: 1) Waist circumference ≥102 cm in men or ≥88 cm in 
women; 2) Triglycerides ≥150 mg/dL; 3) High-density lipid cholesterol < 40 mg/dL in men 
or < 50 mg/dL in women; 4) Blood pressure ≥ 130/85 mmHg or treatment for hypertension; 
5) Fasting blood glucose ≥100 mg/dL or treatment for diabetes.
Statistical analysis
According to guidelines of the NHANES on data analysis and procedure (21), statistical 
analyses should take into account the survey’s complex sampling design to ensure unbiased 
estimation. Specifically, all the analyses used weights and the primary sampling unit and 
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strata supplied by the NHANES. All continuous variables were presented as means ± 
standard errors, and categorical variables were presented as percentages. A t-test compared 
means between continuous variables, and a chi-square test compared categorical variables at 
baseline between participants with and without low muscle mass.
We calculated the quartiles of the measurements of knee extensor strength and designated 
the lowest 25% as low muscle strength in men and women, and compared baseline 
characteristics between participants with and without low muscle strength. The prevalence of 
low muscle mass, low muscle strength, and low muscle mass with or without low muscle 
strength was stratified by sex and race and compared by weighted estimates from chi-square 
tests.
Multivariable logistic regression models with the calculation of odds ratios (ORs) and 95% 
confidence intervals (CIs) were used to assess the individual and joint association of low 
muscle mass and low muscle strength with all-cause mortality. Separate analyses were 
performed for each definition of low muscle mass (ALM and ALM/BMI). All multivariable 
logistic regression models were adjusted for demographic characteristics, including age, sex, 
race, BMI, smoking, alcohol use, education, sedentary time, LTPA, CVD, diabetes, cancer, 
COPD, and CKD. In the joint association, participants were stratified by low muscle mass 
and low muscle strength, and four subgroups were created. The subgroup with normal 
muscle mass and muscle strength was considered the reference group when ORs for the 
three other subgroups were calculated. We also used multivariable logistic regression models 
to explore the effects of the joint associations of MetS (yes vs. no), sedentary time (< 3 
hours vs. ≥3 hours), and LTPA (0, <750, and ≥750 MET/week) with low muscle mass and 
low muscle strength on all-cause mortality. To test for effect modification in each joint 
analysis, we examined the p-value for the interaction term which was added in the 
multivariable logistic regression models. All analyses were conducted using SAS, version 
9.4 (SAS Institute, Inc). Two-sided tests and a 5% significance level were used in the 
analysis.
Results
1. Baseline characteristics stratified by low muscle mass and low muscle strength
A total of 4,449 US adults aged ≥50 and older were included. The prevalence of low muscle 
mass was 23.1% as defined by ALM and 17.0% as defined by ALM/BMI; the prevalence of 
low muscle strength was 19.4%. Basic participant characteristics stratified by low muscle 
mass and low muscle strength are shown in Table 1. Participants with low muscle mass were 
much older, had lower LTPA, and had lower knee extensor peak force than those without 
low muscle mass. Participants with low muscle mass (adjusted by BMI) were more likely to 
have cardiovascular diseases and diabetes, higher BMI and fat mass, systolic blood pressure, 
serum concentration of total triglycerides, fasting glucose, fasting insulin, and HOMA-IR, 
and lower diastolic blood pressure and serum concentrations of high-density lipoprotein than 
those with normal muscle mass. Similarly, participants with low muscle strength were also 
older and had lower LTPA than those without low muscle strength. Anthropometric 
measures except fat mass were significantly lower in those with low muscle strength than 
those with normal muscle strength. Participants with low muscle strength had higher systolic 
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blood pressure, lower diastolic blood pressure, higher serum concentrations of low-density 
lipoprotein, and higher likelihood of CVD, diabetes, cancer, COPD, and CKD compared to 
those without low muscle strength.
2. Prevalence of low muscle mass and low muscle strength
The prevalence of low muscle mass, low muscle strength, and their four combined 
subgroups differed significantly by sex and race (Figure 1). The prevalence of low muscle 
mass (defined by ALM) was significantly lower among men than among women (11.1% vs. 
33.1%), while the prevalence of low muscle mass (defined by ALM/BMI) was higher in men 
than in women (19.3% vs. 15.1%). When the prevalence of four combined subgroups was 
compared between men and women, the trends were not consistent between two definitions 
of low muscle mass (ALM vs. ALM/BMI) (Figure 1A and 1B). The prevalence of low 
muscle mass was much higher in Hispanics (33.0% for ALM, and 28.9% for ALM/BMI) 
and other races (38.6% for ALM, and 22.6% for ALM/BMI) than in non-Hispanic whites 
(22.8% for ALM, 16.8% for ALM/BMI) or blacks (8.4% for ALM, 4.6% for ALM/BMI). 
The prevalence of four combined subgroups among races was similar between two 
definitions of low muscle mass (ALM vs. ALM/BMI). The prevalence of low muscle mass 
with or without low muscle strength was much higher in Hispanics and other races than in 
non-Hispanic whites and blacks (Figure 1C and 1D).
3. Associations of low muscle mass and low muscle strength with all-cause mortality
The results of the associations of low muscle mass or low muscle strength with all-cause 
mortality are presented in Figure 2A. In the fully adjusted models (Model 3), Low muscle 
strength was strongly associated with all-cause mortality (OR 2.34, 95% CI 1.71–3.20). But 
low muscle mass was not significantly associated with increased risk of all-cause mortality 
(OR 1.40, 95% CI 0.91–2.14), unless low muscle mass adjusted by BMI (OR 1.47, 95% CI 
1.08–2.00).
In the joint analyses in which those with normal muscle mass and muscle strength were the 
reference group, incidence of all-cause mortality was significantly higher among participants 
with low muscle strength but with normal muscle mass (OR 2.03, 95% CI 1.27–3.24 for 
ALM; OR 2.53, 95% CI 1.65–3.88 for ALM/BMI) and among those with low muscle 
strength and low muscle mass (OR 2.66, 95% CI 1.53–4.61 for ALM; OR 2.17, 95% CI 
1.29–3.64 for ALM/BMI). However, the combination of low muscle mass with normal 
muscle strength was not significantly associated with all-cause mortality (OR 0.85, 95% CI 
0.44–1.66, for ALM; OR 1.24, 95% CI 0.70–2.20 for ALM/BMI) (Figure 2 B and 2C). The 
interaction between low muscle strength and low muscle mass was not significant on all-
cause mortality (P for interactions =0.19 if low muscle mass was defined by ALM and =0.40 
if defined by ALM/BMI).
4. Joint associations of low muscle mass or low muscle strength with MetS, sedentary 
time, and LTPA
The results of the independent associations of MetS, sedentary time, or LTPA with all-cause 
mortality are presented in Figure 3A, 4A, and 5A, respectively. In the fully adjusted models, 
MetS and sedentary time were not significantly associated with all-cause mortality (OR 
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1.12, 95% CI 0.69–1.83 for MetS and OR 1.18, 95% CI 0.96–1.46 for sedentary time) 
whereas LTPA was significantly associated with increased risk of all-cause mortality (OR 
1.84, 95% CI 1.44–2.35). The results of joint associations of low muscle mass or low muscle 
strength with MetS, sedentary time, and LTPA are shown in Figures 3–5, respectively. 
Among participants without MetS, those with low muscle mass had a significant risk of all-
cause mortality (OR 2.67, 95% CI 1.35–5.27 for ALM and OR 2.18, 95% CI 1.17–4.07 for 
ALM/BMI) (Figure 3B and 3C).
The participants with low muscle mass and sedentary time (≥3 hours) had significant 
association (OR 1.65, 95% CI 1.01–2.68 for ALM and OR 1.71, 95% CI 1.13–2.57 for 
ALM/BMI) with all-cause mortality comparing to those with normal muscle mass and 
sedentary time (<3 hours) (Figure 4B and 4C). As participants with LTPA (≥ 750 MET/
week) and normal muscle mass were the reference groups, those with low muscle mass and 
no LTPA had significant associations (OR 2.93, 95% CI 1.70–5.06 for ALM and OR 2.84, 
95% CI 1.88–4.30 for ALM/BMI) (Figure 5B and 5C). In contrast, there was always 
significantly increased all-cause mortality among participants with low muscle strength, 
regardless of the presence or absence of MetS (Figure 3D), sedentary time (≥3 hours) 
(Figure 4D), and three levels of LTPA (Figure 5D). Interaction testing was statistically 
significant only between low muscle mass (defined by ALM) and LTPA (p=0.04) on all-
cause mortality.
Discussion
In a nationally representative sample of 4,449 US adults aged 50 years and older from the 
NHANES surveys, our study found that low muscle strength was more strongly and 
significantly associated with all-cause mortality than low muscle mass. Furthermore, we 
found that individuals in the subgroup with low muscle mass had significantly increased risk 
for all-cause mortality only when they also had low muscle strength. Consistently, the 
significant associations between low muscle strength and increased risk of all-cause 
mortality persisted regardless of MetS, sedentary time, and LTPA, suggesting that muscle 
strength may be more important than muscle mass in predicting aging-related health 
outcomes in older and elderly adults.
Clark and Manini initially proposed that the term “sarcopenia” be used to describe age-
related reduction of muscle mass and the term “dynapenia” to describe age-related loss of 
muscle strength (6, 30). Over the past three decades, the scientific and medical communities 
have recognized that muscle dysfunction, as reflected by low muscle strength, is a 
debilitating and life-threatening condition in older adults (30). For example, age-related loss 
of muscle strength has been strongly associated with physical disability and mortality in 
older adults (10, 31, 32). In the present study, we provided confirmatory evidence that low 
knee extensor strength indicative of low muscle strength is independently and significantly 
associated with increased risk of all-cause mortality among US older adults regardless of 
muscle mass, MetS risk factors, sedentary time, or LTPA. Our findings in US older adults 
were consistent with previous studies indicating that muscle strength may be an more 
important independent risk factor for all-cause mortality compared with muscle mass among 
elderly Medicare enrolled adults (10). Our findings also support the notion that loss of 
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muscle mass alone may not fully reflect muscular function and that muscle strength should 
be considered an important component in defining sarcopenia.
Longitudinal studies have shown that age-related decline in muscle strength is not 
proportionally related to loss of muscle mass (6). This may, at least in part, explain our 
observation that muscle strength is independently and significantly associated with health 
outcomes regardless of muscle mass. The mechanisms underlying age-related decline in 
muscle strength can be attributed to a combination of neural and muscular factors, such as a 
reduction in descending excitatory drive from supraspinal centers/cortical levels and/or 
suboptimal recruitment and rate coding of motor units, the loss in the intrinsic force-
generating capacity of muscle, changes in actomyosin structure and function, and infiltration 
of adipocytes into muscle fibers (30).
Our study also indicated the potential clinical usefulness of a simple knee extensor strength-
based definition for low muscle strength. First, knee extensor strength can be measured 
clinically with a simple, inexpensive, and reliable strain gauge, which is quick to administer 
for populations at risk. Compared with its counterparts, those with low knee extensor 
strength performed worse in physical performance tests, which include balance, reaction 
time, gait speed, and the Timed Up and Go (16, 33). Those with low knee extensor strength 
also had higher fall risk scores and were 43% more likely to fall at home in the year 
following assessment (16). In addition, the knee extensors are the key muscle group in 
performing sit-to-stand transfers (34), maintaining balance (35), and walking steadily (15).
Loss of muscle mass with aging may not be more useful than low muscle strength in 
predicting all-cause mortality. However, maintenance of muscle mass with advancing age is 
critical, because it serves as a metabolic reservoir that is needed to effectively withstand 
disease (36, 37). Recent studies have suggested that obesity might be closely associated with 
low muscle mass and contribute to an additive or synergistic risk for CVD derived from both 
sarcopenia and obesity (38, 39). The majority of obese persons who develop adverse health 
outcomes, including mortality, typically have a clustering of major and emerging risk 
factors, including insulin resistance, dyslipidemia, and elevated BP, as known as the MetS. 
We found that participants with MetS did not have significantly increased risk of mortality 
compared with those without MetS when they have normal muscle mass. Only participants 
with low muscle mass but without MetS had a significant increased risk of all-cause 
mortality.
Sedentary time and LTPA are highly correlated with muscular adiposity and/or muscle mass 
and function. Although a science advisory from the American Heart Association suggests 
that sedentary behavior could contribute to excess morbidity and mortality (18), there is 
insufficient prospective evidence to establish such an association between sedentary time 
and mortality (19). However, in less-active adults, replacing 1 h of sedentary time with 
activity of light or moderate-to-vigorous intensity was significantly associated with 18% and 
42% lower mortality, respectively (40). We found that participants with a great deal of 
sedentary time had significant increased risk for all-cause mortality when they also had low 
muscle mass or low muscle strength. Lack of LTPA was significantly associated with all-
cause mortality regardless of muscle strength. On the other hand, there were consistently 
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significant associations between low muscle strength and all-cause mortality in participants 
with any LTPA, even LTPA≥750 MET/week. Although there was no statistically significant 
interaction between low muscle strength and LTPA, our data suggest that muscle strength 
and LTPA are independent predictors of all-cause mortality in older and elderly adults.
A major strength of this study is its prospective design based on a nationally representative 
sample of US older adults in the NHANES with a large number of deaths, which provides 
sufficient statistical power to support the generalizability of the findings. Our study also 
included objective measures of muscle mass and knee extensor strength. Furthermore, we 
examined not only the interrelationship of muscle mass and knee extensor strength but also 
their joint associations with physical activity, sedentary time, and MetS. However, there are 
several limitations that deserve consideration. First, the survey assesses only 
noninstitutionalized older adults, omitting nursing home residents or those with severe 
disabilities, who have higher degrees of low muscle mass and low muscle strength. Second, 
the appendicular muscle mass detected by DEXA may not accurately reflect overall muscle 
mass throughout the body. Third, only knee extensor strength was used to represent muscle 
strength because the NHANES lacked a complete set of muscle-strength tests. Fourth, 
sedentary time, leisure-time physical activity, and several medical comorbidities were 
assessed based on self-reported information, which may introduce measurement errors. 
Finally, we acknowledge that logistic regression modeling may not fit mortality data very 
well since it cannot account for time-to-event and censoring information. Additionally, the 
NHANES only provides a baseline assessment of muscle strength, which cannot allow us to 
model longitudinal strength decline.
In conclusion, our study based on a nationally representative sample of US older adults 
demonstrates that low knee extensor strength indicative of low muscle strength was 
independently and significantly associated with an increased risk of all-cause mortality 
regardless of muscle mass, MetS, sedentary time, and LTPA. Our findings indicate that low 
muscle strength may be a more meaningful component of a sarcopenia definition than loss 
of muscle mass in predicting health outcomes. Further investigation is warranted to validate 
different operational criteria for assessing muscle mass, muscle strength, and/or physical 
performance for defining sarcopenia in population studies in predicting various age-related 
health outcomes. Our findings imply that muscle strength appears more important than 
muscle mass are of considerable clinical interest as muscle strength can be improved 
(without increasing muscle mass) in older adults with resistance exercise.
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Figure 1. 
Prevalence of low muscle mass (LMM) and low muscle strength (LMS) in US adults aged 
50 years and older in the NHANES 1999–2002.
A. Prevalence of LMM (ALM) and LMS in single and combination by gender; B. 
Prevalence of LMM (ALM/BMI) and LMS in single and combination by gender; C. 
Prevalence of LMM (ALM) and LMS in single and combination by race; D. Prevalence of 
LMM (ALM/BMI) and LMS in single and combination by race.
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Figure 2. 
Associations of low muscle mass (LMM) and low muscle strength (LMS) with all-cause 
mortality.
A. Individual associations of LMM and LMS with all-cause mortality. B and C. Joint 
associations of LMM and LMS with all-cause mortality in US adults aged 50 years and 
older in the NHANES 1999–2002. The definitions of LMM were based on ALM (B) and 
ALM/BMI (C). Relative Risks (RR) of all-cause mortality were estimated from 
multivariable logistic regression models which were adjusted by age, gender, race, BMI, 
smoking, alcohol use, education, LTPA, sedentary time, CVD, diabetes, cancer, COPD, and 
CKD. CI: confidence interval. P for interaction = 0.235 in B, and 0.432 in C.
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Figure 3. 
Joint associations of low muscle mass (LMM) and MetS, or low muscle strength (LMS) and 
MetS with all-cause mortality.
Individual association of MetS with all-cause mortality was shown in A. The definitions of 
LMM were based on ALM (B) and ALM/BMI (C) in the joint analyses of LMM and MetS; 
the joint associations of LMS and MetS with all-cause mortality were shown in D. Relative 
Risks (RR) of all-cause mortality were estimated from multivariable logistic regression 
models which were adjusted by age, gender, race, BMI, smoking, alcohol use, education, 
LTPA, sedentary time, CVD, diabetes, cancer, COPD, and CKD. P for interaction = 0.058 in 
A, 0.212 in B, and 0.317 in C.
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Figure 4. 
Joint associations of low muscle mass (LMM) and sedentary time, or low muscle strength 
(LMS) and sedentary time with all-cause.
Individual association of sedentary time with all-cause mortality was shown in A. The 
definitions of LMM were based on ALM (B) and ALM/BMI (C) in the joint analyses of 
LMM and sedentary time; the joint associations of LMS and sedentary time with all-cause 
mortality were shown in D. Relative Risks (RR) of all-cause mortality were estimated from 
multivariable logistic regression models which were adjusted by age, gender, race, BMI, 
smoking, alcohol use, education, LTPA, sedentary time, CVD, diabetes, cancer, COPD, and 
CKD. P for interaction = 0.651 in A, 0.808 in B, and 0.807 in C.
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Figure 5. 
Joint associations of low muscle mass (LMM) and LTPA, or low muscle strength (LMS) and 
LTPA with all-cause mortality.
Individual associations of LTPA with all-cause mortality were shown in A. The definitions 
of LMM were based on ALM (B) and ALM/BMI (C) in the joint analyses of LMM and 
LTPA; the joint associations of LMS and LTPA with all-cause mortality were shown in D. 
Relative Risks (RR) of all-cause mortality were estimated from multivariable logistic 
regression models which were adjusted by age, gender, race, BMI, smoking, alcohol use, 
education, LTPA, sedentary time, CVD, diabetes, cancer, COPD, and CKD. P for interaction 
= 0.038 in A, 0.152 in B, and 0.187 in C.
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